CHA1: A New Combinatorial Therapy That Reciprocally Regulates Wnt and JAK/STAT/Interferon Signaling to Re-program Breast Tumors and the Tumor-Resident Landscape.
M. K. Alamoudi, M. E. Chipman, F. H. Deleso-Frechette, A. M. Bogis, R. S. Alqurashi, K. Li, R. Zhang, M. Castañer, G. Triantafillou, C. G. Herbosa, C. Carland, A. J. Lee, K. S. Gillani, K. E. Paulson, A. S. Yee
CHA1, a combination of EGCG and decitabine, reprograms TNBC tumors and their microenvironment by inhibiting Wnt and activating JAK/STAT/IFN signaling, enhancing PD-L1 expression and T-cell infiltration.
bioRxiv · Mar 25, 2022 · PreprintCancer Biology